Omeros Corporation — Stato Patrimoniale (NASDAQ:OMER) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 181.04 M419.27 M590.97 M378.27 M277.08 M325.63 M Totale passività 301.79 M395.49 M380.16 M268.56 M264.08 M142.37 M Patrimonio netto totale -120.75 M23.78 M85.68 M-24.98 M-182.61 M-121.23 M Totale passività e patrimonio netto 181.04 M419.27 M590.97 M378.27 M277.08 M325.63 M Debito totale 237.33 M314.11 M315.71 M213.16 M188.31 M68.93 M Indebitamento netto 102.38 M156.81 M120.81 M41.35 M98.22 M-102.87 M

Notizie

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates (OMER)

Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript

Omeros Corporation batte le stime sugli utili nel Q4 2025

Omeros: Yartemlea Can Own The Label And Still Split The Market (NASDAQ:OMER)

Le azioni Omeros salgono con l’inizio delle prime spedizioni commerciali di YARTEMLEA

Omeros stock rises as first commercial YARTEMLEA shipments begin

Omeros begins commercial distribution of TA-TMA treatment Yartemlea

Omeros VP Borges sells $750k in shares

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (NASDAQ:OMER)